

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                       |                                    |
|-----------------------|------------------------------------|
| <b>Name of entity</b> | <b>Cynata Therapeutics Limited</b> |
| <b>ABN</b>            | <b>98 104 037 372</b>              |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                           |
|----------------------------|---------------------------|
| <b>Name of Director</b>    | <b>Peter Gordon Webse</b> |
| <b>Date of last notice</b> | <b>14 November 2013</b>   |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Direct and Indirect   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Unlisted options held in name of wife – Mrs Kay Joan Webse  |
| <b>Date of change</b>   | 30 November 2013  |
| <b>No. of securities held prior to change</b>   | a. 107,500 Ordinary Shares - Direct;<br>b. 102,500 Listed Options – Exercise Price \$0.20 Expiry 31 December 2014 - Direct; and<br>c. 25,000 Unlisted Options – Exercise Price \$3.98 Expiry 30 November 2013 - Indirect. |
| <b>Class</b>  | a. Ordinary Shares;<br>b. Listed Options; and<br>c. Unlisted Options.   |
| <b>Number acquired</b>  | Nil   |
| <b>Number disposed</b>  | See "Nature of Change" below.   |
| <b>Value/Consideration includes brokerage/gst</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>                     | Nil   |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |   |
|---|---|
| <b>No. of securities held after change</b>  | a. 107,500 Ordinary Shares - direct;<br>b. 102,500 Listed Options – Exercise Price \$0.20 Expiry 31 December 2014 – direct. |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Expiry of 25,000 Unlisted Options on 30 November 2013   |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder (if issued securities)</b>  | N/A |
| <b>Date of change</b>  | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| <b>Interest acquired</b>   | N/A |
| <b>Interest disposed</b>   | N/A |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   | N/A |
| <b>Interest after change</b>   | N/A |

**Part 3 – +Closed period**

|   |     |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | N/A |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | N/A |
| If prior written clearance was provided, on what date was this provided?  | N/A |

+ See chapter 19 for defined terms.